Disc Medicine, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Disc Medicine, Inc. (IRON) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 43.21 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-06
- Disc Medicine, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 43.21M shares, a 34.93% increase year-over-year.
- Disc Medicine, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 43.17M shares, a 180.08% increase year-over-year.
- Disc Medicine, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 43.09M shares, a 181.96% increase year-over-year.
- Disc Medicine, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 43.04M shares, a 181.94% increase year-over-year.
- Disc Medicine, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 40.36M shares, a 167.03% increase from fiscal 2020.
- Disc Medicine, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 15.12M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 43.21M shares 10-Q · filed 2022-05-06 | 43.19M shares derived: average of 2 quarters · filed 2022-05-06 | 43.16M shares derived: average of 3 quarters · filed 2022-05-06 | 43.13M shares derived: average of 4 quarters · filed 2022-05-06 |
| 2021-12-31 | 43.17M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 43.13M shares derived: average of 2 quarters · filed 2022-03-10 | 43.10M shares derived: average of 3 quarters · filed 2022-03-10 | 40.36M shares 10-K · filed 2022-03-10 |
| 2021-09-30 | 43.09M shares 10-Q · filed 2021-11-15 | 43.07M shares derived: average of 2 quarters · filed 2021-11-15 | 39.43M shares 10-Q · filed 2021-11-15 | 33.39M shares derived: average of 4 quarters · filed 2022-05-06 |
| 2021-06-30 | 43.04M shares 10-Q · filed 2021-08-12 | 37.56M shares 10-Q · filed 2021-08-12 | 30.16M shares derived: average of 3 quarters · filed 2022-05-06 | 26.44M shares derived: average of 4 quarters · filed 2022-05-06 |
| 2021-03-31 | 32.03M shares 10-Q · filed 2022-05-06 | 23.72M shares derived: average of 2 quarters · filed 2022-05-06 | 20.91M shares derived: average of 3 quarters · filed 2022-05-06 | 19.50M shares derived: average of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | 15.41M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 12.07M shares 10-K · filed 2021-03-29 | 15.32M shares derived: average of 3 quarters · filed 2022-03-10 | 15.12M shares 10-K · filed 2022-03-10 |
| 2020-09-30 | 15.28M shares 10-Q · filed 2021-11-15 | 15.27M shares derived: average of 2 quarters · filed 2021-11-15 | 15.02M shares 10-Q · filed 2021-11-15 | |
| 2020-06-30 | 15.27M shares 10-Q · filed 2021-08-12 | 14.88M shares 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | 14.50M shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |